Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Amortizatization of Intangibles of $102.0 million for Q2 2012, up 7.37% year-over-year from $95.0 million in Q3 2011, and up 0.99% quarter-over-quarter from $101.0 million in Q1 2012.
Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Amortizatization of Intangibles for 4 consecutive years, with $102.0 million the latest figure, recorded in Q2 2012.
- In Q2 2012, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million; the TTM figure through Jun 2012 stood at $388.0 million (up 26.38% YoY), while the FY2011 annual figure was $353.0 million, up 30.26% from the prior year.
- Amortizatization of Intangibles grew to $102.0 million in Q2 2012 per CELG-RI's latest filing, from $101.0 million in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $102.0 million in Q2 2012 and bottomed at $59.0 million in Q3 2009.
- Historically, Amortizatization of Intangibles has averaged $80.3 million across 4 years, with a median of $75.5 million in 2009.
- Annual changes were most pronounced in 2010 — Amortizatization of Intangibles dropped 6.41% — and 2011, when it jumped 41.79%.
- Bristol Myers Squibb's Amortizatization of Intangibles stood at $78.0 million in 2009, then decreased by 6.41% to $73.0 million in 2010, then increased by 26.03% to $92.0 million in 2011, then gained by 10.87% to $102.0 million in 2012.
- Business Quant data shows CELG-RI's Amortizatization of Intangibles at $102.0 million in Q2 2012, $101.0 million in Q1 2012, and $92.0 million in Q4 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 984.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 600.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 102.00 Mn |
| Jun 30, 2012 | 102.00 Mn |
| Mar 31, 2012 | 101.00 Mn |
| Mar 31, 2012 | 101.00 Mn |
| Dec 31, 2011 | 92.00 Mn |
| Dec 31, 2011 | 92.00 Mn |
| Sep 30, 2011 | 93.00 Mn |
| Sep 30, 2011 | 93.00 Mn |
| Jun 30, 2011 | 95.00 Mn |
| Jun 30, 2011 | 95.00 Mn |
| Mar 31, 2011 | 73.00 Mn |
| Mar 31, 2011 | 73.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 66.00 Mn |
| Sep 30, 2010 | 66.00 Mn |
| Jun 30, 2010 | 67.00 Mn |
| Jun 30, 2010 | 67.00 Mn |
| Mar 31, 2010 | 65.00 Mn |
| Mar 31, 2010 | 65.00 Mn |